ERYTECH Announces the Hosting of a KOL Event as the TRYbeCA-1 Phase 3 Trial in Second-line Pancreatic Cancer Nears Complete Enrollment

  • Post author:
  • Post category:Newsroom

ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announces the hosting of a Key Opinion Leader (KOL) Event to discuss the medical need in pancreatic cancer and the potential role of eryaspase in this setting.